Median Effective Dose (ED50) of Remimazolam Combined with Different Oxycodone Doses for Painless Gastroscopy in Adults

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500105928

Enrollment

Unknown

Registered

2025-07-15

Start date

2025-07-15

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroscopy examination

Interventions

N1 Group:Intravenous administration of oxycodone 0.05 mg/kg

N2 Group:Intravenous administration of oxycodone 0.075 mg/kg

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients scheduled for painless gastroscopy in our hospital, regardless of gender, aged 18-60 years, ASA grade I or II, BMI between 18-24 kg/m^2.

Exclusion criteria

Exclusion criteria: Age 60 years; ASA grade >=III; overweight (BMI >24 kg/m^2); hepatic or renal insufficiency; presence of severe cardiovascular or cerebrovascular diseases, acute or chronic respiratory system diseases, or obstructive sleep apnea syndrome; history of mental illness, cognitive dysfunction, or abuse of sedatives or analgesic drugs; allergy to study drugs such as remimazolam or oxycodone; gastroscopy duration >30 minutes; and inability to sign the informed consent form.

Design outcomes

Primary

Measure	Time frame
Median effective dose (ED50);Remimazolam dosage;Oxycodone dosage;	—

Secondary

Measure	Time frame
Onset time;Recovery time;Time to recovery of orientation;Duration of procedure;Respiratory depression;Hypotension;Adverse reactions;	—

Countries

China

Contacts

Public ContactYang Fangfang

People's Hospital of Fuyang City

Yangff0505@163.com+86 182 5536 3858

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026